BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37161535)

  • 21. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma.
    Jones C; Baker SJ
    Nat Rev Cancer; 2014 Oct; 14(10):. PubMed ID: 25230881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The genetic signatures of pediatric high-grade glioma: no longer a one-act play.
    Diaz AK; Baker SJ
    Semin Radiat Oncol; 2014 Oct; 24(4):240-7. PubMed ID: 25219808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
    Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR-cas9 screening identified lethal genes enriched in Hippo kinase pathway and of predictive significance in primary low-grade glioma.
    Mijiti M; Maimaiti A; Chen X; Tuersun M; Dilixiati M; Dilixiati Y; Zhu G; Wu H; Li Y; Turhon M; Abulaiti A; Maimaitiaili N; Yiming N; Kasimu M; Wang Y
    Mol Med; 2023 May; 29(1):64. PubMed ID: 37183261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
    Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
    Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone H3 K27M mutations in adult cerebellar high-grade gliomas.
    Nakata S; Nobusawa S; Yamazaki T; Osawa T; Horiguchi K; Hashiba Y; Yaoita H; Matsumura N; Ikota H; Hirato J; Yoshimoto Y; Yokoo H
    Brain Tumor Pathol; 2017 Jul; 34(3):113-119. PubMed ID: 28547652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes.
    Wang Q; Li J; Zhu J; Mao J; Duan C; Liang X; Zhu L; Zhu M; Zhang Z; Lin F; Guo R
    Clin Transl Med; 2022 Jun; 12(6):e882. PubMed ID: 35692096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orthotopic Transplantation of Human Paediatric High-Grade Glioma in Zebrafish Larvae.
    Larsson S; Kettunen P; Carén H
    Brain Sci; 2022 May; 12(5):. PubMed ID: 35625011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
    Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
    Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications.
    Buczkowicz P; Bartels U; Bouffet E; Becher O; Hawkins C
    Acta Neuropathol; 2014 Oct; 128(4):573-81. PubMed ID: 25047029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
    Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
    Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone H3 K27 alterations in central nervous system tumours: Challenges and alternative diagnostic approaches.
    Kurdi N; Mokanszki A; Mehes G; Bedekovics J
    Mol Cell Probes; 2022 Dec; 66():101876. PubMed ID: 36414128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
    Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
    Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification.
    Gianno F; Giovannoni I; Cafferata B; Diomedi-Camassei F; Minasi S; Barresi S; Buttarelli FR; Alesi V; Cardoni A; Antonelli M; Puggioni C; Colafati GS; Carai A; Vinci M; Mastronuzzi A; Miele E; Alaggio R; Giangaspero F; Rossi S
    Pathologica; 2022 Dec; 114(6):422-435. PubMed ID: 36534421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
    Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
    Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer.
    Pajovic S; Siddaway R; Bridge T; Sheth J; Rakopoulos P; Kim B; Ryall S; Agnihotri S; Phillips L; Yu M; Li C; Milos S; Patel P; Srikanthan D; Huang A; Hawkins C
    Nat Commun; 2020 Dec; 11(1):6216. PubMed ID: 33277484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
    Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.